| AC Immune is a clinical stage biopharmaceutical company focused on developing medicine for neurodegenerative diseases. Co.'s clinical stage product candidates include: ACI-35.030, which targets pathological Tau and is intended as a disease-modifying treatment for Alzheimer's disease (AD) and other Tauopathies; Semorinemab, which is designed to slow the prion-like propagation of Tau pathology; ACI-24, in which it owns the global rights to ACI-24 and it develops ACI-24 in-house for AD and Down syndrome-related AD; and diagnostic candidates, in which it continues to develop its complementary diagnostic product candidates for Tau, a-syn (with Life Molecular Imaging SA) and TDP-43. The ACIU average annual return since 2016 is shown above.
The Average Annual Return on the ACIU average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ACIU average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACIU average annual return calculation with any dividends reinvested as applicable (on ex-dates).